Trial Profile

Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rucaparib (Primary)
Indications Advanced breast cancer; Carcinoma; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms RIO

Most Recent Events

16 Jul 2020 Status changed from active, no longer recruiting to completed.
19 Dec 2016 Status changed to active, no longer recruiting.
11 Oct 2016 Recruitment is expected to complete early 2017, as per the trial design presented at 41st European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com